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This study aimed to analyze the occurrence of skin toxicity caused by drugs used in the 
protocol of neoadjuvant and adjuvant chemotherapy among women with breast cancer. 
Patient records of 72 women who were subject to this therapy between 2003 and 2006 
were assessed. Of the 558 cycles of chemotherapy, 152 adverse events were registered. 
There were 37 registrations of dermatological toxicity, of those, 20 were extravasations that 
affected 17 women. Nine reports of hardened local injury, local fibrosis, pain, and hyperemia 
were registered during neoadjuvancy. In adjuvancy, among the 11 extravasations registered 
there were reports of hardened local injury, fibrosis and local pain. Lack of follow-up records 
for both periods was observed. Registration of the events and reports by the nursing team 
are essential to monitor the sites of venous puncture during the chemotherapy treatment, 
besides measuring and making a photographic record of the site.
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Materials; Nursing.
Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, WHO Collaborating Centre for Nursing Research 
Development, SP, Brazil:
1 RN, Ph.D. in Nursing, Professor. Email: thaisog@eerp.usp.br, email: marislei@eerp.usp.br.
2 RN, Ph.D. in Nursing, Associate Professor. Email: maclapis@eerp.usp.br, email: amalmeid@eerp.usp.br.
682
www.eerp.usp.br/rlae
Toxicidade dermatológica em mulheres com câncer de mama 
submetidas à quimioterapia
O objetivo deste estudo foi analisar a ocorrência de toxicidade dermatológica, provocada 
por drogas utilizadas no protocolo de quimioterapia neoadjuvante e adjuvante, entre 
mulheres com câncer de mama. Foram avaliados 72 prontuários de mulheres submetidas 
a essa terapia, entre 2003 e 2006. De 558 ciclos de quimioterapia, foram registrados 
152 eventos adversos, 37 de toxicidade dermatológica, e, desses, 20 eram ocorrências 
de extravasamento em um total de 17 mulheres. Observou-se nove ocorrências na 
neoadjuvância com registros nos prontuários de lesão endurecida no local, fibrose local, 
dor e hiperemia. Na adjuvância, dos 11 extravasamentos registrados, destacam-se 
lesão endurecida no local, fibrose e dor local. Houve falta de registro de seguimento 
e avaliação dos eventos adversos para os dois períodos. O registro das intercorrências 
pela equipe de enfermagem é essencial para o acompanhamento dos sítios de punções 
venosas, utilizados durante o tratamento quimioterápico, além da mensuração e registro 
fotográfico do local.
Descritores: Quimioterapia; Neoplasias da Mama; Extravasamento de Materiais 
Terapêuticos e Diagnósticos; Enfermagem.
Toxicidad dermatológica en mujeres con cáncer de mama sometidas a 
quimioterapia
El objetivo de este estudio fue analizar la ocurrencia de toxicidad dermatológica provocada 
por drogas utilizadas en el protocolo de quimioterapia neoadyuvante y adyuvante entre 
mujeres con cáncer de mama. Fueron evaluadas 72 fichas de mujeres sometidas a esta 
terapia de 2003 a 2006. De 558 ciclos de quimioterapia, fueron registrados 152 eventos 
adversos, 37 de toxicidad dermatológica; de estos, 20 fueron ocurrencias de extravasación 
de líquido ocurridos en un 17 mujeres. Se observó 9 ocurrencias en la quimioterapia 
neoadyuvante con registros en las fichas de lesión endurecida en el local, fibrosis local, 
dolor e hiperemia. En la quimioterapia adyuvante, de las 11 extravasaciones registradas, 
se destacan lesión endurecida en el local, fibrosis y dolor local. Hubo falta de registro 
de seguimiento y evaluación de los eventos adversos para los dos períodos. El registro 
de las interocurrencias por el equipo de enfermería es esencial para el acompañamiento 
de los sitios de punciones venosas utilizados durante el tratamiento de quimioterapia, 
además de mensuración y registro fotográfico del local.
Descriptores: Quimioterapia; Neoplasias de la Mama; Extravasación de Materiales 
Terapéuticos y Diagnósticos; Enfermería.
Introduction
Antineoplastic chemotherapy or use of chemical 
agents, singly or in combination, has been one of the 
principle modes of treatment for malignant tumors. 
Nonetheless, the indiscriminate attack promoted by 
chemotherapeutic agents on cancer or normal cells 
generates undesirable effects, known and feared by 
individuals who need this type of treatment(1). These 
effects are called adverse events, and include any 
unfavorable symptom, sign or disease, including 
abnormal laboratory findings, temporarily associated 
with the use of treatment or medical procedure(2).
The adverse effects of chemotherapeutic drugs have 
varying frequencies and intensities, according to the 
drugs used, and can be divided into non-hematological, 
which include gastrointestinal, pulmonary, cardiac, 
hepatic, neurological, renal, bladder and dermatological 
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toxicities, reproductive disorders, metabolic alterations, 
allergic reactions and fatigue; and hematological, which 
include leukopenia, anemia, thrombocytopenia and 
febrile neutropenia(1).
The adverse dermatological events occur in the 
tissue around the area of drug application. This group 
includes changes such as: phlebitis, rash, pain, erythema 
and tissue necrosis secondary to extravasation of 
vesicant drugs out of the venous bed. They may also 
occur systemically, alopecia being the most common, 
followed by less common changes such as erythema, 
urticaria, photosensitivity, hyperpigmentation and 
changes to the nails(1).
In addition to these adverse events, extravasation 
may occur in the administration of the chemotherapeutics. 
This is a term used to describe the unintentional 
administration of vesicant solution or medication into 
areas outside of the venous system(3-4). The incidence of 
extravasation of vesicant drugs, published in the scientific 
literature, is 0.01 to 6.5%, but there is a possibility of 
underreporting of cases(1,3). Morbidity is related to the 
amount of drug extravasated, its concentration, the 
location of extravasation, the type of device used in 
venous access, the conditions of health of the patient 
and the interval between the occurrence of the event 
and its recognition and treatment(3-4).
The extravasation of vesicant drugs causes severe 
irritation with vesicle formation and tissue destruction(5), 
which may cause functional damage, neurological 
alterations, alterations in body image and, principally, 
the patient’s loss of trust in the health professional(3).
There are irritant drugs that, in this case, provoke 
cutaneous reactions of lesser intensity, such as pain and 
burning, but even when infused properly can cause pain 
and an inflammatory reaction along the blood vessel 
used for the infusion(1).
Also in relation to the extravasation of vesicant drugs, 
for each one there are procedures and antidotes that 
can be administered immediately after the occurrence of 
extravasation, through the same needle, subcutaneously 
around the site of extravasation, after aspiration of the 
highest quantity possible of the infiltrated drug.
The objective of the application of the antidotes 
is to limit the local inflammatory process, inactivate 
and remove the remaining drug and its use should 
be prescribed by a doctor or be defined by protocol 
approved by the institution(1).
Some signs and symptoms may be present 
immediately or several days after infusion. Immediate 
reactions are: burning, local discomfort and erythema, 
whereas later reactions include: pain, edema, 
induration, ulceration, vesicles, necrosis, inflammation 
and cellulitis(1).
It is thought that knowledge of collateral effects 
and of the alternatives to control and prevent these 
are indispensable for the management of oncological 
patients. The care of patients and their families include 
guidance on the adverse effects related to chemotherapy 
and these should be based on understandable 
information, reinforcing the benefits of the drugs and 
of the alternatives for the management of the collateral 
effects.
This study was part of a project that evaluated the 
toxicity presented by women with breast cancer during 
chemotherapy, and aims to analyze the occurrence of 
dermatological toxicity provoked by drugs used in the 
protocol of neoadjuvant and adjuvant chemotherapy 
among women followed in the Mastology Outpatient 
Clinic of the Clinical Hospital, Faculty of Medicine of 
Ribeirao Preto, University of Sao Paulo (HCFMRP-USP).
The relevance of this is based on the fact that 
the institution has obtained good results with the 
Commitment to Hospital Quality and, seeking a seal of 
quality, is organizing the protocols of care. The results 
of this study helped with elements to the chemotherapy 
protocols.
Methodology
This study was approved by the Ethics Committee 
of the Clinical Hospital of the Faculty of Medicine of 
Ribeirao Preto, University of Sao Paulo, under number 
8602/2007, along with the request for waiver of the 
free prior informed consent form. It was carried out 
at the Mastology Service of HCFMRP-USP that, during 
the study period, preferably used the protocol of the 
combination of Docetaxel 50mg/m2 and Epirubicin 
75mg/m2 for chemotherapy in women with breast 
cancer in neoadjuvant treatment. For adjuvant 
chemotherapy, Cyclophosphamide 600mg/m2 and 
Epirubicin 60mg/m2 or other schemes were used, 
according to medical evaluation.
For this study secondary data was used, collected 
from medical records of women with breast cancer, 
attended at the Mastology Outpatient Clinic between the 
years 2003 and 2006, and that underwent chemotherapy 
using the neoadjuvant and adjuvant regimens, already 
mentioned. These schemes were selected because, during 
the study period, they were the most frequently used. The 
choice of data from hospital records was based on the fact 
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that the hospital records register constitutes an important 
means of communication between health professionals(5) 
and as this was the first phase of the project it brought 
benefits to the design of a prospective study.
To develop the study, a list of women undergoing 
chemotherapy for gynecologic cancer during the study 
period was first obtained from the Central Chemotherapy 
HCFMRP-USP. In a first review of this relationship, 
women undergoing chemotherapy for other types of 
gynecological cancer, such as cancer of the cervix and 
ovary were excluded. Of 404 records that were reviewed 
72 were selected, of women who met the inclusion 
criteria: age between 30 and 60 years; chemotherapy 
as first treatment option, use of the neoadjuvant and 
adjuvant chemotherapy regimens proposed for this 
study; chemotherapy completed by December 2006. 
For data collection, an instrument was designed with 
information on identification data, data about the 
diagnosis, results of the hemograms performed before 
each cycle of chemotherapy, dosage of chemotherapy 
used in neoadjuvant and adjuvant, post-chemotherapy 
adverse effects, data of possible hospitalization during 
chemotherapy and data on the surgical procedure.
Results
Records of 72 women aged between 30 and 60 
years were studied, most of them being over 45 years 
of age. There was a predominance of white women 
(83.3%) and the breast involved more frequently was 
the left (58%) (Table 1).
Table 1 - Distribution of women undergoing chemotherapy 
for breast cancer by, age, color, and laterality of the 
tumor. Ribeirao Preto, 2008
Characteristic
Number and percentage (%) 
of women
Age
30-35 years 3 (4.1%)
36-40 years 12 (16.6%)
41-45 years 16 (22.2%)
46-50 years 9 (12.5%)
51-55 years 20 (28%)
56-60 years 12 (16.6%)
Color
White 60 (83.3%)
Black 2 (2.7%)
Mixed 10 (14 %)
Laterality of the tumor
Left 42 (58%)
Right 30 (42%)
by IIIb with a frequency of 27.7% of them. Of the 
surgical treatments performed, 40% were registered as 
tumorectomy with axillary lymphadenectomy (AL) and 
34.7% as simple mastectomy with AL (Table 2).
Table 2 - Distribution of women undergoing chemotherapy 
for breast cancer, according to staging and type of 
surgery. Ribeirao Preto, 2008
Disease stage Total
IIa 12 (16.6%)
IIb 15 (21%)
IIIa 25 (34.7%)
IIb 20 (27.7%)
Type of surgery
Tumorectomy + AL + mammary plastic 
surgery 
5 (7%)
Quadrantectomy +AL 4 (5.5%)
Mastectomy + AL + mammary reconstruction 3 (4.1%)
Margin expansion + AL 1 (1.4 %)
Halsted mastectomy + LA 1 (1.4 %)
No surgery carried out 2 (2.7%)
During the chemotherapy, a total of 558 cycles were 
performed, with description of various complications 
that interfered in the duration of treatment. It was not 
possible, during the review of medical records, to identify 
the degree of toxicity of the non-hematologic adverse 
events, because the adverse events reported in the 
medical or nursing records were merely cited, without 
description, making it difficult to assess the degree of 
toxicity presented.
The records presented 77 registrations of adverse 
events during the period of neoadjuvant therapy, 18 
being of hematologic toxicity and 59 of non-hematological 
toxicity. In the adjuvant chemotherapy 75 adverse 
events were recorded, 50 being of non-hematological 
toxicity and 25 of hematological toxicity (Table 3).
Among the non-hematologic toxicities, there were 
a total of 37 dermatological registrations, darkened 
venous pathway being prevalent in the neoadjuvant and 
adjuvant periods, with 23.7% and 12% respectively. 
The occurrence of hardened veins was described in 10 
records, divided equally between the neoadjuvant and 
adjuvant periods (Table 3).
Another complication observed was extravasation 
during the administration of chemotherapy, which 
occurred in 17 (23.6%) women, however, there were 
20 records of extravasation, of which nine were in the 
neoadjuvant and 11 in the adjuvant phase. This fact 
shows that some women had more than one occurrence 
of extravasation in different cycles, or even in the same 
cycle (Table 4).
The IIIa clinical stage of breast cancer was observed 
most, with a frequency of 34.7% of the women, followed 
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Table 3 - Frequency distribution of non-hematologic 
toxicity in women undergoing chemotherapy, Ribeirao 
Preto, 2008 (N=109)
Non-hematologic 
toxicity Neoadjuvant Adjuvant Total 
Dermatological Total = 26 Total = 11 37 (34%)
Darkened venous 
pathway 14 (23.7%) 6 (12%) 20 (18.3%)
Indurated veins 10 (16.9%) 5 (10%) 15 (13.8%)
Others 2 (3.3%) - 2 (1.8%)
Others Total = 33 Total = 39 72 (66%)
Total 59 50 109
Table 4 - Distribution of women undergoing 
chemotherapy for breast cancer, according to occurrence 
of extravasation. Ribeirao Preto, 2008
Extravasation Neoadjuvant Adjuvant Total
Number of events 09 11 20
Drug
Epirubicin 08 08 16
Docetaxel 01 - 01
Cyclophosphamide - 03 03
Cycles
1 04 02 06
2 02 01 03
3 02 02 04
4 01 06 07
The follow-up and consequences of these 
extravasations appear poorly reported, and there were 
few reports recorded in the medical records, neither 
by the nursing staff of the Chemotherapy Center, the 
Mastology Outpatient Clinic or the ward in which the 
women with breast cancer were hospitalized.
Of the 20 registrations of extravasation, it 
was observed that nine (45%) occurred during the 
neoadjuvant therapy phase and the consequences 
registered in medical records were: two (22.2%) reports 
of indurated lesion in the area, one (11.1%) reference 
of not presenting alterations, one (11.1%) of fibrosis 
in the area and one (11.1%) report of pain, hyperemia 
and indurated lesion at the site, while in four (44.4%) 
instances there is no record of the follow up action. In 
the adjuvant phase, of the 11 extravasations registered, 
two (18%) reports of indurated lesion in the area were 
observed and one (9.1%) of fibrosis and local pain, which 
was referred to physiotherapy to implement resources 
that improve pain and movement of the affected hand, 
in eight (72.7%) instances no record of the action were 
observed.
Table 5 shows the actions related to the occurrence 
of extravasation. It was observed that, in spite of the 
protocol defined by the institution, the registrations 
vary regarding application with the occurrence of 
extravasation of the same drug, as shown below.
Table 5 - Distribution of women undergoing chemotherapy 
for breast cancer, according to application of extravasation 
protocol. Ribeirao Preto, 2008
Drug Action Number of occurrences
Epirubicin 
Aspirate blood 5
Hydrocortisone administered IV
Local ice 
Aspirate blood 1
Hydrocortisone administered IV
Local ice 
Hirudoid®
Aspirate blood 6
Hydrocortisone administered IV
Bicarbonate of soda and 
dexamethasone SC
Local ice 
Aspirate blood 2
Hydrocortisone administered IV
Aspirate blood 1
Hydrocortisone administered IV
Compressive dressing
Aspirate blood 1
Cyclophosphamide 
No procedure 2
Aspirate blood 1
Hydrocortisone administered IV
Compressive dressing
Docetaxel
Aspirate blood 1
Hydrocortisone administered IV
Discussion
Chemotherapy takes prominence in the management 
of tumors, and has improved the prognosis of many 
neoplasms, but the majority of chemotherapeutic 
agents can cause dermatologic toxicity. Vesicant drugs 
have been used routinely for decades, and there is a 
gap in informed evidence and in their control. When 
an extravasation occurs or is suspected, the infusion 
is stopped and the affected area should be inspected 
and the treatment given with the correct antidote to the 
drug(3-4,6).
The occurrence of extravasation of chemotherapy 
in this study (23.6%) was higher than that found in 
the literature, which ranges from 0.01 to 6.5%(3), but 
there are few studies that report on the occurrence 
of extravasation. Because it is an event that can lead 
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to significant morbidity, this high incidence points to 
the need for adequate training of professionals who 
administer chemotherapy in the institution studied, who 
value the recording of most of these occurrences(1).
Preventive measures are strongly advocated in the 
scientific literature, such as observation, cooperation 
on the part of patients and recognition of the effects of 
drugs by the team of professionals. Other preventive 
measures, such as avoiding punctures near the joints 
and bony prominences; skill, experience and scientific 
technical expertise of the professional; puncture with 
minimal trauma using small caliber catheters; testing of 
the vein initially with isotonic solution; catheter fixation 
with visualization of the venous pathway; valorization 
of patients’ complaints about stinging and burning; 
avoidance of fragile veins (dorsal hand antecubital 
fossa and feet); infusing 50 to 10 ml of saline between 
one drug and another, are complemented with the 
recommendation of recording all actions performed by 
the nurse(4,7-8). However, in this study it was not possible 
to identify preventive measures established by the 
nursing team in their records, except for the complaints 
of women during infusion.
A lack of consensus for the management of 
extravasation was also observed in the scientific 
literature, as several antidotes for the same drug were 
indicated as was the use or non-use of corticosteroids. 
Although there is no consensus about localized drug 
use, the local application of ice for all drugs, except for 
the vinca alkaloids and oxaliplatin, when heat should be 
used, is an empirical measure used for many years, but 
with no evidence of benefits(7-9). The protocol used in 
the service where this study was conducted is consistent 
with that suggested in the international literature, except 
for the use of sodium bicarbonate, which has not been 
recommended for its vesicant effect when given outside 
the vessel(8-9).
During the review of medical records, it was 
observed that nursing professionals value the recording 
of the occurrence or suspicion of extravasation. 
However, monitoring these complications was poorly 
reported by nursing teams that assist women with 
breast cancer (Chemotherapy Center, Outpatient Clinic 
and Ward). COFEN Resolution Nº 210/1998(10) states 
that it is duty of the nurse “to plan, organize, supervise, 
execute and evaluate all activities of Nursing, for clients 
undergoing antineoplastic chemotherapy, categorizing 
it as a service of high complexity, grounded in Nursing 
care methodology”. Thus, the registration of all 
interventions performed by nurses during the infusion 
of chemotherapy is the duty of nurses and after the 
occurrence of extravasation, registration and monitoring 
are of fundamental importance in the quality of care 
provided to oncological patients.
Proper documentation of extravasation 
demonstrates the practice of nursing care. The inverse 
of this may be interpreted as a failure in this care. The 
recording should be made for all steps of the infusion of 
chemotherapeutic agents, from the venipuncture until 
removal, including the infusion of serums and other 
medications(11).
Documentation must be performed when there 
is suspicion of extravasation or if it is confirmed and 
must cover all actions taken by the nurse, as well as the 
responses to these interventions(11).
The follow-up of the lesions also must be registered 
with a clear and detailed description of the affected 
area, and the patient’s response to treatment. For better 
documentation and evaluation of actions, the nurse can 
make use of the photographic record of the area where 
the extravasation occurred or was suspected(11-12).
Conclusion
A high number of extravasation records in the service 
were observed, which reveals how nurses, working in 
the field, value and are attentive to the occurrence or 
suspicion of extravasation. However, it was observed 
that the registering of follow-up was not as valued by 
these professionals. Issues such as continuing education 
for them are extremely important, so that it becomes 
more evident that the nursing work performed with 
these patients is of fundamental importance.
Moreover, these nurses should be encouraged 
to carry out scientific research to identify more 
effective strategies for prevention and intervention of 
extravasation, improving the quality of life of patients 
and valorizing the work of nurses.
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